Talimogene laherparepvec
A practical guide to the handling and administration of talimogene laherparepvec in Europe
... Abstract: Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in ...disease. Talimogene ...
14
Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition
... Talimogene laherparepvec (T-Vec), a first-in-class therapeutic cancer virus, was approved by the FDA for the treatment of advanced melanoma in October ...
8
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
... of talimogene laherparepvec to initiate regional and systemic anti-tumor activity is sup- ported by responses in both uninjected non-visceral and some visceral melanoma ...following talimogene laher- ...
8
Imaging Manifestations of Pseudoprogression in Metastatic Melanoma Nodes Injected with Talimogene Laherparepvec: Initial Experience
... SUMMARY: Talimogene laherparepvec is an oncolytic virus recently approved for targeted treatment of advanced ...with talimogene laherparepvec does not necessarily indicate ...
5
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
... of Talimogene laherparepvec (T-VEC) T-VEC is a modified herpes simplex virus, type 1 (HSV-1) [1] that has undergone genetic modifications to promote selective tumor cell replication, while reducing viral ...
8
Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab
... Due to worsening disease and declining performance status, the patient’s treatment options were limited. Ipili- mumab was deemed inappropriate due to the recent clos- tridium difficile infection and worsening fatigue. ...
7
Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
... population, talimogene laherparepvec was well tolerated in patients with stage IIIB/C or IVM1a ...with talimogene laherparepvec compared with ...with talimogene laherparepvec ...
13
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
... Talimogene laherparepvec (T-VEC), a first-in-class viral oncolytic immunotherapy [1], was approved in the United States in 2015 for the local treatment of unresectable, cuta- neous, subcutaneous and nodal ...
11
Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
... 11 Talimogene laherparepvec is a modified herpes simplex virus (HSV) type-1 designed to specifically replicate in and lyse tumor ...cells, talimogene laherparepvec is engineered to express the ...
7
Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
... 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US Food and Drug Administration approval for the treat- ment of melanoma in the skin and lymph ...
8
Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
... Methods: We reviewed 10 consecutive cases of stage IIIC to stage IVM1b melanoma patients that received T-VEC plus checkpoint inhibitor(s) therapy (pembrolizumab, ipilimumab/nivolumab, or[r] ...
7
Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma
... as talimogene laherparepvec (T-VEC), has been identified as an attractive oncolytic virus for cancer therapy based on preclinical tumor studies and results from early-phase clinical trials and a large ran- ...
10
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
... regression. Furthermore, this process may cause a local inflammatory-like response in lesions, resulting in a period of “pseudo-progression” before response [15, 22]; thus, al- ternative measures of clinical response may ...
9
Melanoma treatment in review
... and talimogene laherparepvec) or in trials (in gray – durvalumab, CK-301, avelumab, atezolizumab, gp100 vaccine, resiquimod, and CAR-T cells) for cutaneous melanoma ...with talimogene ...
15